Background Patients with sickle cell anaemia (SCA) are routinely managed with folic acid
and paludrine in Nigeria. However, since the licensing of hydroxyurea (HU) by Food and …

Background: The pathophysiology of sickle cell disease (SCD) is complex and involves nitric
oxide depletion, increased inflammation/adhesion molecules and vaso-occlusion in addition …

Hydroxyurea (HU) is used as a disease-modifying agent in sickle cell disease (SCD). Its
beneficial effects have been ascribed to inhibition of the sickling process through increase of …

Background: The vast majority of births with sickle cell anemia occur in Africa 1 and early-life
mortality, generally before age five years, is as high as 90% 2, 3. Hydroxyurea was …

Sickle cell disease (SCD) is common in tribal belt of Gujarat, but not addressed effectively as
it should be with effective use of Hydroxyurea, supportive care and counseling. In our single …

Background: The vast majority of births with sickle cell disease (SCD) occur in Africa and
90% are thought to die before the age of five. Hydroxyurea (HU) is the only drug approved …

Background: The clinical prospects of hydroxyurea therapy in the management of sickle cell
disease (SCD) require evaluation in the Nigerian setting to develop indigenous guidelines …

Background: Despite a high incidence of sickle cell anemia, hydroxyurea (HU) treatment is
rarely used in the DR Congo. This study aims to assess the efficacy of HU, the incidence of …

Background. Despite a large body of evidence that hydroxyurea is effective for sickle cell
anemia (SCA), utilization with the “maximum tolerated dose” regimen has been low. 1 …

Sickle cell disease (SCD) is a group of inherited disorders of hemoglobin synthesis. It is
prevalent in different parts of the world, including the Kingdom of Saudi Arabia. The disease …